Showing results (1511-1520 of 1,542) with videos related to

Sort By:
Pageof 155
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 29, 2025
Prognostic significance and accuracy of oncologists' estimates of survival time in recurrent ovarian cancerSharon H Nahm, Belinda E Kiely, Rachel L O'Connell, et al.
Neurology|June 22, 2018
Longitudinal analysis of impulse control disorders in Parkinson diseaseJean-Christophe Corvol, Fanny Artaud, Florence Cormier-Dequaire, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 7, 2024
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancerRachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 14, 2019
Examining the Reserve Hypothesis in Parkinson's Disease: A Longitudinal StudyPei-Chen Lee, Fanny Artaud, Florence Cormier-Dequaire, et al.
Journal of Hepatology|March 24, 2009
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosageChun-Jen Liu, Po-Huang Lee, Deng-Yn Lin, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 28, 2022
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit StudyYeh Chen Lee, Madeleine T King, Rachel L O'Connell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2026
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 TrialPatrick Schöffski, Roberta Sanfilippo, Javier Martín-Broto, et al.
World Journal of Gastroenterology|August 30, 2014
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrenceChun-Jen Liu, Juliana Chang, Po-Huang Lee, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 22, 2024
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomesLucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
Hepatology Communications|June 9, 2018
Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis BShiu-Feng Huang, Il-Chi Chang, Chih-Chen Hong, et al.
Pageof 155